Presurgical targeted therapy with Everolimus for angiomyolipoma associated with tuberous sclerosis complex
Guo Gang
Cai Wei
Zhang Fan
Zhang Xu
Abstract：Objective:To evaluate the feasibility and safety of a presurgical treatment approach with Everolimus for angiomyolipoma (AML)associated with tuberous sclerosis complex (TSC)and explore its potential ability to re-duce the surgical morbidity.Methods:One TSC-AML patient was treated with Everolimus and subsequently under-went resection.Toxicities,surgical complications,and tumor responses were monitored.Results:The patient re-ceived super-selective renal arterial embolization combined with nephron-sparing resection for right side renal tumor. Then,she received Everolimus (10 mg Qd)for two months.The change in primary renal tumors was a 60% (5.1 cm)decrease after two months.The patient received drug discontinuance for 3 months before operation.She received nephron sparing surgery for her left side renal tumor.There was no recurrence or progression during a follow-up pe-riod of 12 months.Conclusions:The administration of preoperative Everolimus therapy can impact the size and densi-ty of the primary tumor and appears safe and feasible.More TSC-AML patients can receive nephron-sparing partial nephrectomy.
Keywords：Everolimusrenal tumortuberous sclerosis complexangiomyolipoma
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 155-158 )